<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36099751</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>10</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-5967</ISSN><JournalIssue CitedMedium="Internet"><Volume>156</Volume><PubDate><Year>2022</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology</Title><ISOAbbreviation>J Clin Virol</ISOAbbreviation></Journal><ArticleTitle>Comparative analysis of three multiplex platforms for the detection of respiratory viral pathogens.</ArticleTitle><Pagination><StartPage>105274</StartPage><MedlinePgn>105274</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jcv.2022.105274</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1386-6532(22)00206-2</ELocationID><Abstract><AbstractText Label="BACKGROUND">Acute viral respiratory infections are a major health burden in children worldwide. In recent years, rapid and sensitive multiplex nucleic acid amplification tests (NAATs) have replaced conventional methods for routine virus detection in the clinical laboratory.</AbstractText><AbstractText Label="OBJECTIVE/STUDY DESIGN">We compared BioFire® FilmArray® Respiratory Panel (FilmArray V1.7), Luminex NxTag® Respiratory Pathogen Panel (NxTag RPP) and Applied Biosystems TaqMan Array Card (TAC) for the detection of eight viruses in pediatric respiratory specimens. Results from the three platforms were analyzed with a single-plex real-time RT-PCR (rRT-PCR) assay for each virus.</AbstractText><AbstractText Label="RESULTS">Of the 170/210 single-plex virus-positive samples, FilmArray detected a virus in 166 (97.6%), TAC in 163 (95.8%) and NxTag RPP in 160 (94.1%) samples. The Positive Percent Agreement (PPA) of FilmArray, NxTag RPP and TAC was highest for influenza B (100%, 100% and 95.2% respectively) and lowest for seasonal coronaviruses on both FilmArray (90.2%) and NxTag RPP (81.8%), and for parainfluenza viruses 1- 4 on TAC (84%). The Negative Percent Agreement (NPA) was lowest for rhinovirus/enterovirus (92.9%, 96.7% and 97.3%) on FilmArray, NxTag RPP and TAC respectively. NPA for all three platforms was highest (100%) for both parainfluenza viruses 1- 4 and influenza A and B, and 100% for human metapneumovirus with TAC as well.</AbstractText><AbstractText Label="CONCLUSION">All three multiplex platforms displayed high overall agreement (&amp;gt;90%) and high NPA (&amp;gt;90%), while PPA was pathogen dependent and varied among platforms; high PPA (&amp;gt;90%) was observed for FilmArray for all eight viruses, TAC for six viruses and NxTag RPP for 4 viruses.</AbstractText><CopyrightInformation>Copyright © 2022 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Banerjee</LastName><ForeName>Dithi</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Children's Mercy Hospital, Kansas City, MO, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hassan</LastName><ForeName>Ferdaus</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Children's Mercy Hospital, Kansas City, MO, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Avadhanula</LastName><ForeName>Vasanthi</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piedra</LastName><ForeName>Pedro A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, United States of America; Department of Pediatrics, Baylor College of Medicine, Houston, TX, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boom</LastName><ForeName>Julie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Baylor College of Medicine, Houston, TX, United States of America; Texas Children's Hospital, Immunization Project, Baylor College of Medicine, Houston, TX, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sahni</LastName><ForeName>Leila C</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Baylor College of Medicine, Houston, TX, United States of America; Texas Children's Hospital, Immunization Project, Baylor College of Medicine, Houston, TX, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weinberg</LastName><ForeName>Geoffrey A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>University of Rochester School of Medicine &amp;amp; Dentistry, Rochester, NY, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lindstrom</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rha</LastName><ForeName>Brian</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harrison</LastName><ForeName>Christopher J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Children's Mercy Hospital, Kansas City, MO, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Selvarangan</LastName><ForeName>Rangaraj</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Children's Mercy Hospital, Kansas City, MO, United States of America. Electronic address: rselvarangan@cmh.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 IP001049</GrantID><Acronym>IP</Acronym><Agency>NCIRD CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 IP001158</GrantID><Acronym>IP</Acronym><Agency>NCIRD CDC HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Clin Virol</MedlineTA><NlmUniqueID>9815671</NlmUniqueID><ISSNLinking>1386-6532</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017934" MajorTopicYN="N">Coronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D025202" MajorTopicYN="Y">Molecular Diagnostic Techniques</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060885" MajorTopicYN="N">Multiplex Polymerase Chain Reaction</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018184" MajorTopicYN="N">Paramyxoviridae Infections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012141" MajorTopicYN="Y">Respiratory Tract Infections</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014777" MajorTopicYN="Y">Virus Diseases</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Comparative performance</Keyword><Keyword MajorTopicYN="N">Multiplex assays</Keyword><Keyword MajorTopicYN="N">Respiratory virus</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>8</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>13</Day><Hour>18</Hour><Minute>21</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36099751</ArticleId><ArticleId IdType="doi">10.1016/j.jcv.2022.105274</ArticleId><ArticleId IdType="pii">S1386-6532(22)00206-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle>